Xcout IntelStarling Oncology, Inc.
Starling Oncology, Inc., formerly The Oncology Institute, is a value-based oncology company advancing cancer care in the community setting. Founded in 2007, the company offers cutting-edge, evidence-based cancer treatments, including clinical trials and transfusions, to a large patient population. It operates as an integrated oncology platform serving patients, providers, and health plans across multiple markets with a focus on delivering high-quality, patient-centered care.
Subscribe to see Starling Oncology, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Starling Oncology, Inc. at a glance
Starling Oncology, Inc. is a biotech company headquartered in Cerritos, United States. It is publicly listed (STLN) with a market capitalisation of $654.8M. Xcout tracks 20 named people at Starling Oncology, Inc., including Daniel Virnich FACHE (CEO & Executive Director).
Starling Oncology, Inc. leadership
- Daniel Virnich FACHECEO & Executive Director
- Daniel VirnichChief Executive Officer
- Dan AyerRegional President
- Kiran AnnavarapuRegional President
- Stacy ConstantineRegional President
- Robert CarterChief Financial Officer
14 more named people on record for Starling Oncology, Inc., with roles, board committees and tenure — see the full roster →
Starling Oncology, Inc. competitors
A few of Starling Oncology, Inc.'s closest competitors — see the full list of competitors and alternatives →
City of Hope is a nonprofit biomedical research and healthcare organization headquartered in Duarte, California, specializing in cancer treatment, diabetes research, and other serious diseases. It serves patients through hospitals and clinics while advancing translational research, developing therapies, and providing clinical trials.
The START Center for Cancer Research is a global oncology research organization dedicated to advancing cancer treatments and clinical trials. The center operates multiple office locations across the United States and Europe.
Sierra Hematology & Oncology provides specialized cancer treatment and hematology care services across multiple locations in California. The medical center offers a multidisciplinary approach that includes medical oncology, radiation oncology, blood disorder treatments, and personalized patient navigation for individuals battling cancer.
Crown Bioscience is a global contract research organization (CRO) headquartered in California that specializes in translational oncology and immuno-oncology drug discovery and development. The company provides comprehensive discovery, preclinical, and translational research platforms.
Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle. Additionally, Champions Oncology offers Lumin Bioinformatics, a comprehensive software platform and data tool filled with insights from research services and clinical studies, accessible through annual subscriptions. The company distributes its offerings through various channels, including online platforms, word-of-mouth referrals, and a dedicated sales team, reaching both patients and healthcare professionals. Established in 1985, Champions Oncology, Inc. is based in Hackensack, New Jersey, and was formerly known as Champions Biotechnology, Inc. until its name change in April 2011.
Nxtcure Labs operates as an AI-driven contract research organization (CRO) that provides end-to-end clinical trial management services for oncology studies. Its platform utilizes thirteen purpose-built AI agents to handle routine trial operations across start-up, data, safety, and documentation, combined with a human review queue for critical medical, regulatory, and financial decisions.
Get Starling Oncology, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Starling Oncology, Inc.? Suggest a correction · Work at Starling Oncology, Inc.? Claim this profile
Is this your company? Add the Xcout Intel badge to your website
Free, for any company on Xcout Intel. It links visitors to this profile.
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Starling Oncology, Inc. in Xcout Intel
- 20 named people with titles, LinkedIn and board committees
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access